HIMS and NVO Related Headlines
Go Back- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
- Hims & Hers expands platform to include Eli Lilly weight loss medications
- Morgan Stanley Comments Eli Lilly (LLY) and Medicare GLP-1 Obesity Coverage
- Wolfe: 'We're observing some reports of GLP-1 users refreshing their wardrobes as weight loss progresses'
- Canaccord on Hims and Hers (HIMS): 'Novo partnership goes live; near-term headwind to revenue, long-term tailwind to the story'
- HIMS to offer Wegovy and Ozempic through partnership with Novo Nordisk
- Hims shares set for best week on record after new Novo Nordisk deal
- TD Cowen: 'Wegovy Injection may be declining'
- HIMS partners with Novo Nordisk, shifts US weight loss strategy
- Hims soars 44% on report Novo Nordisk to sell weight-loss drugs on its platform
- Hims shares jump on deal to offer Novo's Wegovy, Ozempic on its platform
- FDA issues 30 warning letters to telehealth firms over GLP-1 claims
- Hims & Hers Health (HIMS) stock: Should you buy the dip after massive selloff?
- Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies
- Hims and Hers (HIMS) PT Lowered to $20 at Leerink Partners
- Novo Nordisk sues Hims & Hers over patent infringement
- Novo Nordisk sues Hims & Hers over compounded semaglutide products
- Novo Nordisk jumps, Hims shares plummet after pulling $49 weight-loss pill
- Hims & Hers Health (HIMS) said to stop offering weight loss pill
- FDA scrutiny rattles Hims & Hers stock
- FDA moves to restrict copycat GLP-1 weight loss drugs
- Hims & Hers stock falls after FDA warns against illegal copycat drugs
- TD Cowen Reiterates Hold Rating on Hims and Hers (HIMS)
- Truist: 'Defending Lilly: LLY strong position helps guard their share in a crowded GLP-1 landscape'
- Novo Nordisk threatens legal action over Hims & Hers semaglutide pill
- Leerink: 'there is no reason why HIMS shouldn't evaluate these launches for every subsequent weight loss product'
- Wolfe Research on Eli Lilly (LLY): 'we question the legality of HIMS' ability to market an oral semaglutide'
- Wells Fargo on Eli Lilly (LLY): 'Compounders Strike Again, but We See Little Risk to Near-Term Growth'
- BMO Capital: 'Novo Mgmt Meetings Highlight Deep Strategic Challenges'
- Hims stock surges as Wegovy pill copy offered at $49, Novo shares fall
- Hims & Hers adds compounded semaglutide pills starting at $49 monthly
- Hims & Hers Health (HIMS) launches a copy of Wegovy pill at $49/month
- Hims stock falls after lawmakers propose GLP-1 compounding restrictions
- Novo Nordisk cuts cash prices for Wegovy and Ozempic to $199 monthly
- Hims & Hers in talks with Novo Nordisk to offer Wegovy treatments
- Walmart (WMT) Adds Home Delivery for Ozempic, Other Refrigerated Drugs - Bloomberg
- U.S. FDA sends drug advertising warning letters to Lilly, Novo, Hims
- Hims&Hers gains after court rejects Eli Lilly’s case against Willow
- Novo Nordisk offers Ozempic at $499 per month to eligible US cash-paying customers
- Novo Nordisk files 14 new lawsuits over compounded semaglutide drugs
- Hims & Hers Health, Inc. (HIMS) on Watch; Novo Nordisk (NVO) Expands Legal Action to Protect US Patients From Non-FDA-approved Compounded 'Semaglutide'
- Eli Lilly stock rises, Novo Nordisk shares jump on potential Medicare coverage
- Hims&Hers stock pares losses on data despite Novo Nordisk litigation fears
- Hims & Hers (HIMS) reportedly makes statement on congressional letter to FDA
- Hims & Hers Health, Inc. (NYSE: HIMS) Falls, Group Of 81 Bipartisan Lawmakers Sign Letter On Glp-1 Action
- Hims & Hers (HIMS) launches ads targeting patient personalization in newspapers
- Morgan Stanley on Compounder Lawsuits: 'experts think the courts would likely refuse to dismiss the case and that it could take 2-3 years to resolve'
- LifeMD (LFMD) stock rises on continued Wegovy partnership with Novo Nordisk (NVO)
- Deutsche Bank Reiterates Hold Rating on Hims and Hers (HIMS)
- Morgan Stanley Reiterates Equalweight Rating on Novo Nordisk (NOVOB:DC) (NVO)
- Hims & Hers (HIMS) CEO responds to Novo Nordisk (NVO) news
- Morgan Stanley on Hims and Hers (HIMS): 'The abrupt change could renew concerns over litigation'
- Novo Nordisk (NVO) terminates collaboration with Hims & Hers Health (HIMS) due to concerns about their illegal mass compounding and deceptive marketing
- Hims & Hers stock falls after Novo Nordisk ends weight loss drug pact
- Novo, Hims & Hers engage in war of words after Wegovy deal falls apart
- Hims & Hers Health, Inc. (HIMS) Falls 18% After Pact with Novo Nordisk Ends
HIMS and NVO Related Press Releases
Go Back- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
